In an intellectual property lawsuit filed by Cepheid against Roche, a US district court has stayed a hearing on whether a PCR patent owned by Roche is invalid until the companies finish ongoing arbitration hearings.

In addition, the court has granted a motion by Roche to dismiss Cepheid's request that the court rule a second PCR patent owned by Roche to be unenforceable, ruling that it is not pertinent to the case and that Cepheid has "manufactured a controversy" over the patent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.